Does GLS by feature-tracking CMR predict medium-term MACE better than LVEF and CMR markers of infarct severity in revascularized STEMI patients?
GLS by feature-tracking CMR provides superior and incremental prognostic value over LVEF and traditional CMR markers for predicting MACE in revascularized STEMI patients.
GLS by feature-tracking-CMR strongly and independently predicted the occurrence of medium-term MACE in contemporary revascularized ST-elevation myocardial infarction patients. Importantly, the prognostic value of GLS was superior and incremental to LVEF and CMR markers of infarct severity.
Reindl et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: